mono or combination immunotherapy for hnscc?
Published 5 years ago • 130 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
2:03
aspen-03: evorpacept in combination with pembrolizumab in patients with advanced hnscc
-
33:50
immunotherapy for recurrent or metastatic hnscc: what are the practical considerations?
-
1:58
standard of care treatments for patients with cmel, cscc, hnscc and acc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
2:26
sd-101 plus pembrolizumab for hnscc
-
1:37
the future role of immunotherapy in head and neck cancer
-
1:09
the future role of immunotherapy in head and neck cancers
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
11:57
immunotherapy in hnscc
-
6:11
pembrolizumab: monotherapy versus combination therapy
-
4:41
immunotherapy combinations for hnscc
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
2:08
combining radiotherapy and immunotherapy in head and neck cancer
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
10:42
what is new in melanoma?
-
0:54
neon-1 & neon-2: alpn-202 alone or with pembrolizumab in patients with advanced malignancies
-
1:20
comparing petosemtamab and pembrolizumab in hnscc with existing therapies
-
6:00
optimizing first-line immunotherapy for recurrent or metastatic hnscc